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Introduction: Anti-VEGF treatment has proven effective in recurrent ovarian cancer. However, the identification of
the patients most likely to respond is still pending. It is well known that the angiogenesis is regulated by several
other pro-angiogenic proteins, e.g. the platelet - derived growth factor (PDGF) system and the fibroblast growth
factor (FGF) system. These other signaling pathways may remain active or become upregulated during anti-VEGF
treatment.
The aim of the present study was to investigate if potential changes of PDGF-BB, PDGF-AA, and FGF2 before and
during bevacizumab treatment had predictive value for early progression or survival. Furthermore, we wanted to
investigate the importance of serum VEGF in the same cohort.
Methods: This study included 106 patients with chemotherapy-resistant epithelial ovarian cancer who were treated
with single agent bevacizumab as part of a biomarker protocol. Patients were evaluated for response by the
Response Evaluation Criteria In Solid Tumors (RECIST) and/ or Gynecologic Cancer Intergroup (GCIG) CA125 criteria.
Serum samples were collected at baseline and prior to each treatment. FGF2, PDGF-BB, PDGF-AA were quantified
simultaneously using the Luminex system, and VEGF-A was measured by ELISA. Eighty-eight baseline samples were
avaliable for FGF2, PDGF-BB, PDGF-AA analysis, and 93 baseline samples for VEGF.
Results: High baseline serum VEGF was related to poor overall survival. Furthermore, high serum PDGF-BB and
FGF2 was of prognostic significance. None of the markers showed predictive value, neither at baseline level nor
during the treatment.Introduction
The crucial importance of angiogenesis in tumor growth
[1,2] has made it a very attractive target for anti-cancer
treatment [3]. In particular, focus has been on the vascu-
lar endothelial growth factor (VEGF) system due to its
central role in the angiogenic process. Over the last few
years, bevacizumab, a monoclonal antibody against
VEGF, has proven effective in ovarian cancer treatment,
both in the frontline setting combined with chemother-
apy [4,5] and in recurrent platinum-sensitive [6] and re-
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illustrated a clear improvement in progression-free sur-
vival (PFS) for platinum-resistant ovarian cancer patients
treated with combined chemotherapy and bevacizumab
compared to patients only treated with chemotherapy
[10] (the AURELIA study). However, it is well known
that only a subgroup of patients will benefit from bevaci-
zumab. Furthermore, the treatment is costly and has
some rare but serious side effects. Taken together, there
is an obvious need for validated biomarkers [11-13] as a
rational basis for patient selection.
A number of studies have demonstrated a relation be-
tween high pre-operative baseline serum VEGF and poor
prognosis in ovarian cancer in either univariate or multi-
variate analysis [14-16] and two studies, including the
earlier results from our cohort, have demonstrated al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ease prior to commencing bevacizumab treatment
[17,18].
One of the major problems during anti-VEGF treat-
ment seems to be tumor evasion from VEGF blockage
that may involve several complex escape mecha-
nisms [12,13,19,20] including activation of other pro-
angiogenic factors such as the fibroblast-growth factor
(FGF) and/ or the platelet-derived growth factor
(PDGF) system [12,13,19-21]. The PDGF and FGF sys-
tems are believed to interact mutually [22] and con-
tribute with different effects to angiogenesis and the
tumor microenvironment. FGF2 promotes endothelial
cell proliferation and migration [23] whereas PDGF-BB
affects pericyte recruitment and stabilization of the
vasculature [24-27]. PDGF-AA may also participate in
recruitment of the tumor associated stroma that pro-
duces angiogenic factors [3,28]. The vasculature in
tumors that evade the anti-VEGF treatment may ex-
press a higher level of PDGF-BB and develop changes
in vessel morphology [29].
The potential clinical importance of FGF or PDGF to
tumor growth during bevacizumab treatment remains to
be elucidated. It has been suggested that identification of
early escape mechanisms could form the basis of changes
in the treatment regime [12,13], which makes it interest-
ing to examine factors influencing these mechanisms.
The aim of the present study was to investigate PDGF
and FGF serum levels before and during treatment and
to investigate whether their potential changes during the
treatment had predictive value for early progression.
Furthermore, we wanted to investigate the importance
of serum VEGF in this larger cohort.
Materials and methods
Materials
The study included 106 patients with chemotherapy-
resistant epithelial ovarian cancer who were treated with
single agent bevacizumab as part of a marker protocol in
the period from July 2007 to February 2012. The
patients had verified progression of the disease at the
time of inclusion in the protocol. At the time of inclu-
sion, paraffin-embedded formalin-fixed tissue and slides
from the primary operations were collected and under-
went central review by a gyneco-pathologist. Bevacizu-
mab was contraindicated in cases of tumor invasion into
the major vessels, whereas bowel involvement was con-
sidered a relative contraindication. All patients were eva-
luable for response by either RECIST [30] and/or GCIG
CA125 criteria [31]. CT scan was performed at baseline
and at every third cycle, and CA125 was measured prior
to each cycle. Patients received bevacizumab 10 mg/kg
every third week and continued until progression, side-
effects, or patients refusal. The protocol was approvedby the Regional Scientific Ethical Committee for Southern
Denmark. Written informed consent was obtained from
all patients and the Helsinki II Declaration was strictly
observed. Blood samples for biomarker analyses were
collected serially before each cycle. After half an hour of
coagulation, the blood samples were centrifuged at 2000 g
for 10 minutes at room temperature and serum was
subsequently stored at −80°C until use.
Methods
Luminex
PDGF-AA, PDGF-BB, and FGF2 were quantified simul-
taneously using the commercial Fluorokine MAP multi-
plex kits (cat#LAN000 R&D systems, Minneapolis, MN,
USA) on the Luminex analyzer (Luminex Corporation,
Austin, USA). The serum samples were diluted x 5 in
sample diluent provided with the kit. 100 μL of standard,
control, and diluted samples were added to the plate to-
gether with 50 μL of the antibody capture bead mixture,
and the plate was incubated for 2 hours. Then washing
was carried out three times using assay buffer and vac-
uum filtration. Fifty μL of diluted biotin-coupled anti-
body cocktail were added to each well and the plate was
incubated for 1 hour followed by washing. Fifty μL
diluted Streptavidin conjugated with phycoerythrin were
added to the plate and incubated for 30 minutes in dark.
Finally after washing, 100 μL assay buffer were added
and the plate was incubated for 2 minutes, after which
the analysis was carried out on the Luminex analyzer.
All incubations were performed on a plate shaker at
room temperature.
PDGF-AA, PDGF-BB, and FGF2 concentrations were
determinated from three different standard curves show-
ing MFI (Median Fluorescence Intensity) vs. protein
concentrations.
The total coefficients of variation (CV) were determined
from one in house serum pool. CV was 6.9% for PDGF-
AA, 11.6% for PDGF-BB, and 21.8% for FGF2. In cases
where FGF2 was below the detection limit of 16.8 pg/ml
(corrected for dilution), ½ * LOD (8.00 pg/m), was chosen
and inserted as a value (four samples at baseline, three
samples before cycle 2, six samples before cycle 3 and 2
samples before cycle 4).
ELISA
Serum VEGF was measured by Quantikine Human
VEGF Immunoassay (cat#DVE00, SVE00, PDVE00, R&D
systems. The performance of the VEGF-ELISA analysis
has previously been described in the paper dealing with
the first included patients of the protocol (2007–2009)
[17]. The total coefficients of variation (CV) were deter-
mined from one in house serum pool and three controls
of low, medium, and high concentration (RnDSystems),
and were found to be between 11%-19%.
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The concentrations of the biomarkers did not fit a
gaussian-distribution. Correlations between PDGF-AA,
PDGF-BB, FGF2, and VEGF were described by Spear-
man rank correlation coefficient (r). Mann Whitney U
test was used for comparing the medians between the
patients groups (disease control vs. progression) whereas
Wilcoxon signed-rank test was used for comparing the
medians within the groups. Progression-free survival
(PFS) was calculated from start of bevacizumab treat-
ment until progression or death from any cause. The
date of progression was reported for both RECIST alone
as well as for a combination of RECIST and CA125
(whichever came first). Overall survival (OS) was calcu-
lated as the interval from start of bevacizumab treatment
until death from any cause. Kaplan-Meier estimates were
used for univariate overall survival analysis (OS), illu-
strated by survival plots, and the log-rank test was used
for comparing the survival between two groups. A
p-value ≤ 0.05 was considered statistically significant.
Number Cruncher Statistical System (NCSS), version
2007, (Kaysville, UT, USA) software package was used
for the statistical analyses.
Results
Patient characteristics
It appears from Table 1 that serous adenocarcinoma was
the most frequent histological subtype (89%). In three
patients, the primary ovarian tumors were diagnosed as
serous borderline tumors, two with invasive implants
(FIGO III ) and one without invasive implants (FIGO I).
All three patients had recurrence and progression with
invasive implants.
Median age at diagnosis was 57 years. At time of refer-
ral for bevacizumab treatment, patients had received a
median of 4 different chemotherapy regimens (range 2–7),
but most of them were still in a good performance stage
(PS 0/1 87%). The median number of bevacizumab infu-
sions was 4.5 (range 1–64). At time of analysis (April
2012), 9 patients were still receiving bevacizumab.
Twenty-nine (27%) received at least 6 months of treat-
ment (9 cycles), and seven patients (7%) received bevaci-
zumab for at least one year (18 cycles).
Efficacy
For all included patients, median PFS was 3.9 months
(95% C.I. 3.0- 4.2) using the combination of CA125 or
RECIST, and 4.2 months (95% C.I. 3.5- 4.8) using the
RECIST criteria only. Median OS was 7.7 months
(6.3 -8.2). Response rate (RR) was 21% according to the
GCIG CA125 criteria. Partial response (PR), evaluated
by RECIST, was seen in only 5% of the patients, but 52%
of the patients had stable disease (SD) in an intention-
to- treat analysis.Side effects
During bevacizumab treatment, five patients (4.7%)
experienced a gastrointestinal perforation, four patients
(3.8%) had a venous tromboembolic event, one patient
(0.9%) a cerebral embolism, and another patient (0.9%)
an episode of transient ischemic attack (TIA). Four
patients (3.8%) suffered from an ileo-vaginal fistula. A
urine dipstick test prior to each treatment showed pro-
tein 2+ in 25 of the patients (23.6%), but none of the
patients presented > 1 g protein/ 24 h in the following
urine collection. Hypertension [32] grade 2, stage 1,
(140-159/90-99 mm Hg) was seen in 20 (18.7%) of the
patients, in three of them it was present before starting
treatment and in 12 of the cases it was only temporary.
Hypertension grade 3, stage 2, (160/100 mm Hg) was
measured in three of the patients (2.8%) at some point
during the treatment.
Serum PDGF-AA, PDGF-BB, FGF2, and VEGF at baseline
Baseline sera PDGF-AA, PDGF-BB, and FGF2 were
available in 88 of the patients and for VEGF in 93 of the
patients. Medians and ranges are reported in Table 1
and the correlation coefficients between the different
markers are illustrated in Table 2.
As shown in Figure 1, baseline PDGF-AA, PDGF-BB,
FGF2, and VEGF levels were divided into quartiles and
investigated in relation to survival.
For VEGF, lower OS was found in patients with levels
above the median, p = 0.01 which was further accentu-
ated for patients with levels above the 75th quartile,
p = 0.0005.
For PDGF-BB, lower OS was found in patients with
levels above the median, p = 0.02, but with no accentu-
ation at the 75th quartile level. The median level of FGF2
had only marginal prognostic significance, p = 0.07, but
lower OS was seen in patients with levels above the 75th
quartile p = 0.02. PDGF-AA levels did not influence the
survival when dividing according to median or the 75th
quartile level (data not shown).
The same analyses were made in relation to PFS. Only
baseline VEGF above the 75th quartile was related to
poor PFS, p = 0.01 (data not shown).
Serum PDGF-AA, PDGF-BB, FGF2, and VEGF during
treatment
Serum PDGF-AA, PDGF-BB, FGF2, and VEGF were
measured during treatment and investigated in relation
to response. Seventy-nine patients were evaluable for re-
sponse by either RECIST and/or CA125 based on at
least 3 serum samples. As illustrated in Figure 2, there
were no significant differences of PDGF-AA, PDGF-BB,
and FGF2 between the group who progressed (30% of
the patients) after three cycles and the group with stable
disease (70% of the patients). There were no significant
Table 1 Patient characteristics
Number N (%)
Total 106 (100)
Age at diagnosis, median 57
FIGO stage
I 8 (8)
II 8 (8)
III 76 (71)
IV 14 (13)
Histopathological subtype
Serous* 94 (89)
Endometrioid 5 (4)
Serous + clear cell (mixed) 1 (1)
Transitiocellular carcinoma 1 (1)
Carcinosarcoma 1 (1)
Adenocarcinoma 1 (1)
Borderline (with invasive implants) 3 (3)
Number of prior chemotherapy regimens
Median 4
Range 2 - 7
Interval from last chemotherapy regimens
Median 1.8
Range 0.3-14.7 months
Bevacizumab infusions
Median 4.5
Mean 7.1
Range 1 – 64**
≤ 2 cycles 22 (21)
≥ 9 cycles 29 (27)
Performance status at start of bevacizumab treatment
0 40 (38)
1 52 (49)
2 13 (12)
3 1 (1)
Baseline VEGF, median (range) 504 (27–1847)
Baseline PDGF-AA, median (range) 2074.25 (207 – 5476.5)
Baseline PDGF-BB, median (range) 7789 (670–28487)
Baseline FGF2, median (range) 60 (8–234)
* including primary peritoneal and fallopian cancer.
** still receiving bevacizumab.
Table 2 Correlation coefficients between the different
markers
PDGF-AA PDGF-BB FGF2
PDGF-BB r = 0.80 (p < 10-5)
FGF2 r = 0.42 (p < 10-5) r = 0.32 (p = 0.003)
VEGF r = 0.50 (p < 10-5) r = 0.53 (p < 10-5) r = 0.25 (p = 0.02)
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FGF2 at baseline and before response evaluation within
the two groups (data not shown). VEGF decreased from
baseline (p < 10-3) already after the first cycle of treat-
ment in both groups, and remained unchanged until re-
sponse evaluation. None of the markers showed significant
predictive value.
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Figure 1 Overall survival curves generated by the Kaplan-Meier
method according to quartiles for VEGF, PDGF-BB, and FGF2.
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The present study confirms that bevacizumab is effect-
ive as monotherapy in multi-resistant ovarian cancer
patients. The adverse event profile is consistent with
the findings reported in other comparable studies of
bevacizumab in heavily pre-treated ovarian cancer
patients [8]. Remarkably, a number of patients (7%), all
with measurable disease, were treated for at least one
year. There was nothing that separated them from the
rest of the patients as regards histopathological charac-
teristics and they had previously received a median of
five chemotherapy regimens. One of the patients
received the 64th cycle of bevacizumab at the time of
the present evaluation. In contrast, a proportion of
patients did not benefit at all from the treatment and
stopped after short-term treatment due to progression,
toxicity or other symptoms.
We found, in accordance with our previous findings
[17] and reports from other studies [14-16,18], a rela-
tion between high serum VEGF levels and poor OS.
Different cut-off values have been used in the litera-
ture to dichotomize patients with high and low VEGF
values; however, the median VEGF levels are used in
most of the cases. However, a study of 312 patients
by Hefler et al. [14] clearly demonstrated, on survival
plot, an association between preoperative serum VEGF
in the upper 4th quartile and poor OS, which is con-
sistent with our results. High levels of PDGF-BB and
FGF2 may also be of prognostic importance in heavily
pre-treated ovarian cancer patients, and our results are
partly in agreement with Schilder et al. [33] who
reported a relation between plasma PDGF-AB, PDGF-
BB, VEGF and poor OS. However, in the present study
we were not able to demonstrate any significant differ-
ences of PDGF-AA, PDGF-BB, and FGF2 between
patients responding and patients not responding to
the treatment.
The decline in serum VEGF during bevacizumab
treatment in ovarian cancer patients is in line with
the studies by Han et al. [18] and Karihtala et al.
[34]. It should be noted that Han et al. [18] also
investigated plasma VEGF but without finding any
significant changes in plasma VEGF during the treat-
ment. The predictive value of baseline VEGF reported
in the first cohort of our patients with ovarian cancer
[17] was not confirmed in the present study. This dis-
parity clearly illustrates the drawback of small studies.
The risk of such positive results being false positive is
very high.
Concentrations of PDGF and FGF in serum or in
plasma during anti-cancer treatment have not yet been
fully investigated although a decline in serum PDGF-AA
or PDGF-BB has been demonstrated in various cancer
types during chemotherapy and/or radiotherapy [35-37],
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bevacizumab.
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tors (VEGFR-2, FGF and PDGF) [38]. Other reports sug-
gest that plasma PDGF-AB, PDGF-BB, and VEGF may
be stable during treatment with Imatinib Mesylate
[33]. Associations between dynamics or baseline
levels of PDGF and/or FGF and treatment response
have been reported in metastatic colorectal cancer
(mCRC) [35], breast cancer [39], and in metastatic
melanoma [36].
It is obvious that the dynamics of the angiogenic mar-
kers are influenced by the specific type of anticancer
treatment. To the best of our knowledge, this study is
the first to report serum PDGF and FGF measurements
during single agent bevacizumab treatment in ovarian
cancer. The markers presented here did not show pre-
dictive information on early progression and the clinical
value of monitoring these markers during bevacizumab
therapy seems limited. However, it should be noted that
our study used ’single agent targeted treatment’ and that
the PDGF system may react differently to cytostatics
alone or in combination. Similar reservations apply to
the combination of biological treatment and conven-
tional chemotherapy. Furthermore, our patients had
received several lines of treatment and marker dynamics
may differ between first line and subsequent lines of
chemotherapy.In conclusion, the present study confirms the prognos-
tic importance of baseline serum VEGF and also sug-
gests a prognostic value of serum PFGF-BB and FGF2.
The results call for further studies in the early line of
treatment.
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